Perceptive Discovery Becomes First US Provider of At-211 Studies
Boston – October 16, 2026 -- Perceptive Discovery has become the first US provider able to run astatine-211 (At-211) radiopharmaceutical development studies, now available at its US and UK sites through a collaboration with Atley Solutions.
First Atley C100 module purifies At-211 at QMUL laboratory in London
At Perceptive Discovery's laboratory at Queen Mary University of London (QMUL), the first Atley C100 module in the collaboration is installed. It has been used to purify At-211 from an irradiated bismuth-209 target.
A second Atley C100 module is expected at the company's Needham, Massachusetts facility later this month. The Atley C100 is an automated manufacturing platform built specifically for At-211 radiopharmaceuticals.